EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparing a Dual-Species In Vitro Biofilm Model for Testing Antibiofilm Efficacy

Kelli Randmäe, Kairi Lorenz, Marta Putrinš, Tanel Tenson, Karin Kogermann iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Kelli Randmäe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, University of Tartu, Nooruse 1, Tartu 50411, Estonia. Hauptthemen laut MEDLINE: Biofilms, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eesti Teadusagentuur.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All wounds are contaminated, and there is a risk of developing an infection. Furthermore, most wounds contain biofilm and are contaminated by two bacteria, termed dual-species, or more bacteria, termed polybacterial biofilms. New antibacterial and antibiofilm wound care products are constantly being developed to combat this problem. There is a need to develop more biorelevant and reproducible models to test the efficacy of these wound care products. We used an electrospun (ES) gelatin-glucose matrix (Gel-Gluc) as an artificial skin substrate for dual-species biofilm formation using wound pathogens Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, combining them in pairs. When analyzing the biofilms, selective agars were used to differentiate various bacteria from one another while counting. The developed method supported the growth of dual-species biofilm that contained both bacteria up to 108 CFU/Gel-Gluc after 24 h. Over 48 h, there was a decrease in the number of S. aureus in the biofilms. Confocal microscopy imaging allowed monitoring of the location of bacteria in the Gel-Gluc and proved that different species were located closely together. ES polycaprolactone (PCL) fibrous wound dressings containing chloramphenicol (CAM) or ciprofloxacin (CIP), or their pristine analogs, were used to test the model. Both ES fibrous wound dressings were effective in preventing dual-species biofilm formation. PCL-CIP fibrous dressing was also effective in treating biofilms. The efficacy of treatment of E. coli varied in different dual-species combinations of E. coli. The developed dual-species biofilm model on artificial skin (Gel-Gluc) supported the successful growth of different bacterial combinations and proved to be suitable for testing the efficacy of ES fibrous wound dressings in preventing and treating biofilms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsAnti-Bacterial AgentsPseudomonas aeruginosaEscherichia coliStaphylococcus aureusGelatinHumansPolyestersGlucoseMicrobial Sensitivity Tests

Stichwörter der Autor:innen

antibacterialantibiofilmdual-species biofilmelectrospinningin vitro biofilm modelskin wound infectionwound dressings

Substanzen

Anti-Bacterial AgentsGelatinpolycaprolactonePolyestersGlucose

Autor:innen und Institutionen

  • Institute of Pharmacy, University of Tartu, Nooruse 1, Tartu 50411, Estonia.
  • Institute of Technology, University of Tartu, Nooruse 1, Tartu 50411, Estonia.

ORCID-Profile: Karin Kogermann

Förderung

  • Eesti Teadusagentuur

Zitieren

APA

Randmäe, K., Lorenz, K., Putrinš, M., Tenson, T., & Kogermann, K. (2025). Preparing a Dual-Species In Vitro Biofilm Model for Testing Antibiofilm Efficacy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00798

Vancouver

Randmäe K, Lorenz K, Putrinš M, Tenson T, Kogermann K. Preparing a Dual-Species In Vitro Biofilm Model for Testing Antibiofilm Efficacy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00798

BibTeX
@article{Randme2025,
  author = {Randmäe, Kelli and Lorenz, Kairi and Putrinš, Marta and Tenson, Tanel and Kogermann, Karin},
  title = {Preparing a Dual-Species In Vitro Biofilm Model for Testing Antibiofilm Efficacy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00798}
}
Kostenlos starten →